# Vaccitech

- Link: https://100xfounder.com/startup/vaccitech/
- Published: 2024-01-01T00:00:00+05:30
- Author: Ishaan Vardhan

Vaccitech was a biotechnology company spun out of the University of Oxford’s Jenner
Institute in 2016. Its early work included the co-invention and early development
of the Oxford/AstraZeneca COVID-19 vaccine, Vaxzevria. The company later listed 
on Nasdaq.

On 6 November 2023 Vaccitech announced that it had changed its name to Barinthus
Biotherapeutics, trading under the ticker BRNS from 7 November. The company said
the old name suggested a purely vaccine-focused business, while its work had moved
to T-cell immunotherapies for infectious diseases, autoimmunity and cancer. The 
new name comes from a figure in the Arthurian legends described as a guide and navigator.
The old vaccitech.co.uk address now redirects to barinthusbio.com.

In 2026 the company’s lead programme is VTP-1000, an experimental treatment for 
coeliac disease. Barinthus said enrolment in the Phase 1 AVALON trial was complete
with 42 subjects, and that topline data from its multiple-ascending-dose part were
expected in the fourth quarter of 2026. For the second quarter of 2026 it reported
a net loss of $10.6 million and cash of $59.6 million at 30 June.

On 30 September 2025 Barinthus and Clywedog Therapeutics announced an all-stock 
merger. Under the original terms, Barinthus shareholders would own about 34% of 
the combined company and Clywedog’s about 66%; the combined business would be renamed
Clywedog Therapeutics and trade on Nasdaq as CLYD. The merger agreement was amended
in February 2026, and the company’s later filings still describe the deal as pending.
We have not seen confirmation that it has closed.

This is a drug developer, not a product you can buy. It appears on 100xFounder as
part of our coverage of startups and their outcomes.

_This profile is put together from the company’s own pages and published reporting,
checked on 15 October 2026. We have not tested the product, and nothing here is 
paid placement._